Donald L. Very, Jr. Joins InClinica as Chief Technical Analyst, Devices and Diagnostics

Press Releases

Donald L. Very, Jr. Joins InClinica as Chief Technical Analyst, Devices and Diagnostics

 

PHILADELPHIA (April 3, 2018)InClinica, a global, clinical CRO, announced today that Donald L. Very, Jr., Ph.D. has been appointed as Chief Technical Analyst, Devices and Diagnostics. In his new role, Dr. Very will provide his expertise to InClinica’s client companies as they develop their devices and diagnostic assays and seek regulatory approval.

Dr. Very has more than 25 years of industry experience in device development, diagnostic and pharmaceutical assay development, and performance qualification in such diverse clinical areas as oncology, infectious disease, and metabolic disease. He is well-versed in each clinical trial step: research, development, performance validation, clinical trial design and implementation, and regulatory approval.

“We are very excited to welcome Don to the InClinica team,” said James Nolan, CEO at InClinica. “His knowledge of and experience in assay development make him an excellent addition to our team as we continue to strengthen our services and drive more devices to regulatory approval.”

Prior to joining InClinica, Dr. Very founded Naviter Bioanalytics, a private consulting firm specializing in bioanalytical method development. He also served as Vice President, Scientific Strategy, Technology and Research at Helomics Corporation. Additionally, he served as Vice President of Research and Assay Development for Ancera, Inc., Vice President of Immunology and Assay Development for the Institute for Bioanalytics, LLC, and Senior Research Scientist for the Diagnostics Division of Bayer Corporation.

Dr. Very received his Bachelor of Science degree in Biology from the University of Notre Dame, his Master of Science degree in Biology from the University of Texas at San Antonio, and his Doctorate in Microbiology and Immunology from Boston University.

About InClinica

InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.